Chen Shi-Liang, Hu Dan, Chen Tian-Zhu, Shen Si-Yu, Zhao Chen-Fei, Wang Cong, Tong Shi-Yuan, Liu Zhao, Lin Shao-Hua, Jin Li-Xia, He Yi-Bo, Zhang Zhe-Zhong
Department of Clinical Lab, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, People's Republic of China.
Department of Clinical Lab, The Cixi Integrated Traditional Chinese and Western Medicine Medical and Health Group Cixi Red Cross Hospital, Cixi, People's Republic of China.
J Inflamm Res. 2024 Sep 25;17:6743-6764. doi: 10.2147/JIR.S477846. eCollection 2024.
Cancer-associated fibroblasts (CAFs) significantly contribute to tumor progression and the development of resistance to therapies across a range of malignancies, notably breast cancer. This study aims to elucidate the specific role and prognostic relevance of CALU across multiple cancer types.
The association between CALU expression and prognosis, along with clinical characteristics in BRCA, HNSC, KIRP, LGG, and LIHC, was analyzed using data from the TCGA, GTEx, and GEO databases. Transcriptomic analysis of TCGA BRCA project data provided insights into the interaction between CALU and epithelial-mesenchymal transition (EMT) marker genes. Using TIMER and TISCH databases, the correlation between CALU expression and tumor microenvironment infiltration was assessed, alongside an evaluation of CALU expression across various cell types. Furthermore, CALU's influence on TNBC BRCA cell lines was explored, and its expression in tumor tissues was confirmed through immunohistochemical analysis of clinical samples.
This study revealed a consistent upregulation of CALU across several tumor types, including BRCA, KIRP, LIHC, HNSC, and LGG, with elevated CALU expression being associated with unfavorable prognoses. CALU expression was particularly enhanced in clinical contexts linked to poor outcomes. Genomic analysis identified copy number alterations as the principal factor driving CALU overexpression. Additionally, a positive correlation between CALU expression and CAF infiltration was observed, along with its involvement in the EMT process in both CAFs and malignant cells. In vitro experiments demonstrated that CALU is highly expressed in TNBC-BRCA cell lines, and knockdown of CALU effectively reversed EMT progression and inhibited cellular migration. Immunohistochemical analysis of clinical samples corroborated the elevated expression of CALU in tumors, along with alterations in EMT markers.
This comprehensive pan-cancer analysis underscores CALU's critical role in modulating the tumor microenvironment and facilitating cell migration via the EMT pathway, identifying it as a potential therapeutic target.
癌症相关成纤维细胞(CAFs)在多种恶性肿瘤(尤其是乳腺癌)的肿瘤进展和治疗耐药性发展中起着重要作用。本研究旨在阐明CALU在多种癌症类型中的具体作用和预后相关性。
使用来自TCGA、GTEx和GEO数据库的数据,分析CALU表达与预后之间的关联,以及BRCA、HNSC、KIRP、LGG和LIHC中的临床特征。对TCGA BRCA项目数据的转录组分析提供了关于CALU与上皮-间质转化(EMT)标记基因之间相互作用的见解。使用TIMER和TISCH数据库,评估CALU表达与肿瘤微环境浸润之间的相关性,同时评估CALU在各种细胞类型中的表达。此外,探讨了CALU对三阴性乳腺癌(TNBC)BRCA细胞系的影响,并通过对临床样本的免疫组织化学分析证实了其在肿瘤组织中的表达。
本研究揭示了CALU在包括BRCA、KIRP、LIHC、HNSC和LGG在内的几种肿瘤类型中一致上调,CALU表达升高与不良预后相关。CALU表达在与不良结局相关的临床背景中尤其增强。基因组分析确定拷贝数改变是驱动CALU过表达的主要因素。此外,观察到CALU表达与CAF浸润之间呈正相关,并且其参与了CAFs和恶性细胞中的EMT过程。体外实验表明,CALU在TNBC-BRCA细胞系中高表达,敲低CALU可有效逆转EMT进程并抑制细胞迁移。临床样本的免疫组织化学分析证实了CALU在肿瘤中的表达升高以及EMT标记物的改变。
这项全面的泛癌分析强调了CALU在调节肿瘤微环境和通过EMT途径促进细胞迁移中的关键作用,将其确定为一个潜在的治疗靶点。